Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in Guinea pigs

Blood

Volumn 121, Issue 25, 2013, Pages 5088-5097

  Momi, Stefania ^a   Tantucci, Michela ^a   Van Roy, Maarten ^b   Ulrichts, Hans ^b   Ricci, Giovanni ^a   Gresele, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b ABLYNX NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CAPLACIZUMAB; NANOBODY; RISTOCETIN; TIROFIBAN; VON WILLEBRAND FACTOR; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYTIC THERAPY; GUINEA PIG; HUMAN; MALE; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RENAL CLEARANCE; SKIN BLEEDING; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; ANIMAL; BRAIN ARTERY; BRAIN INFARCTION; DISEASE MODEL; DRUG ANTAGONISM; METHODOLOGY; PATHOLOGY; REPERFUSION;

ANIMALS; BRAIN INFARCTION; CEREBRAL ARTERIES; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; GUINEA PIGS; INTRACRANIAL THROMBOSIS; MALE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; REPERFUSION; SINGLE-DOMAIN ANTIBODIES; THROMBOLYTIC THERAPY; VON WILLEBRAND FACTOR;

EID: 84882316231     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-464545     Document Type: Article

References (49)

1. Savage B, Saldívar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996; 84(2):289-297.
2. Chen J, López JA. Interactions of platelets with subendothelium and endothelium. Microcirculation. 2005;12(3):235-246.
3. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2(1):15-28.
4. Quinn MJ, Byzova TV, Qin J, Topol EJ, Plow EF. Integrin aIIbb3 and its antagonism. Arterioscler Thromb Vasc Biol. 2003;23(6): 945-952.
5. Gresele P. Antiplatelet agents in clinical practice and their haemorragic risk. Blood Transfus-Italy. 2013. (in press)
6. Schulman S, Spencer FA. Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. J Thromb Haemost. 2010;8(4):641-650.
7. Liao JK. Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer? Circulation. 2007;115(12): 1615-1621.
8. O'Donnell MJ, Hankey GJ, Eikelboom JW. Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review. Stroke. 2008;39(5):1638-1646.
9. Gresele P, Agnelli G. Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002;23(1):25-32.
10. Sandercock PA, Counsell C, Gubitz GJ, Tseng MC. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev. 2008;(3): CD000029.
11. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA. 2000;284(12): 1549-1558.
12. Adams HP Jr, Effron MB, Torner J, et al; AbESTTII Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39(1): 87-99.
13. Seitz RJ, Hamzavi M, Junghans U, Ringleb PA, Schranz C, Siebler M. Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: preliminary observations. Stroke. 2003;34(8):1932-1935.
14. Adams HP Jr, del Zoppo G, Alberts MJ, et al; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007; 38(5):1655-1711.
15. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2009;(4): CD000213.
16. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24): 1581-1587.
17. Murray V, Norrving B, Sandercock PAG, Ter ént A, Wardlaw JM, Wester P. The molecular basis of thrombolysis and its clinical application in stroke. J Intern Med. 2010; 267(2):191-208.
18. van Schie MC, van Loon JE, de Maat MP, Leebeek FW. Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost. 2011;9(5): 899-908.
19. Wieberdink RG, van Schie MC, Koudstaal PJ, et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke. 2010;41(10):2151-2156.
20. Hanson E, Jood K, Karlsson S, Nilsson S, Blomstrand C, Jern C. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost. 2011;9(2): 275-281.
21. Gresele P, Momi S. Inhibitors of the interaction between von Willebrand Factor and platelet GPIb/IX/V. Handb Exp Pharmacol. 2012; (210):287-309.
22. Crescente M, Thomas GM, Demers M, Voorhees JR, Wong SL, Ho-Tin-Noé B, Wagner DD. ADAMTS13 exerts a thrombolytic effect in microcirculation. Thromb Haemost. 2012;108(3): 527-532.
23. Ulrichts H, Silence K, Schoolmeester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011;118(3):757-765.
24. Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood. 2012; 120(17):3603-3610.
25. Giannini S, Mezzasoma AM, Leone M, Gresele P. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry. Haematologica. 2007; 92(12):1647-1654.
26. Giannini S, Mezzasoma AM, Guglielmini G, Rossi R, Falcinelli E, Gresele P. A new case of acquired Glanzmann's thrombasthenia: diagnostic value of flow cytometry. Cytometry B Clin Cytom. 2008; 74(3):194-199.
27. Momi S, Falcinelli E, Giannini S, et al. Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. J Exp Med. 2009; 206(11):2365-2379.
28. Kageyama S, Yamamoto H, Nagano M, Arisaka H, Kayahara T, Yoshimoto R. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br J Pharmacol. 1997;122(1):165-171.
29. Momi S, Pitchford SC, Alberti PF, Minuz P, Del Soldato P, Gresele P. Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice. Thromb Haemost. 2005; 93(3):535-543.
30. Brecher G, Cronkite EP. Morphology and enumeration of human blood platelets. J Appl Physiol. 1950;3(6):365-377.
31. Rossiello MR, Momi S, Caracchini R, et al. A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. J Thromb Haemost. 2005;3(11):2554-2562.
32. Molero L, Farré J, García-Mendez A, et al. Endothelin-1 induced proinflammatory markers in the myocardium and leukocytes of guinea-pigs: role of glycoprotein IIB/IIIA receptors. Cardiovasc Res. 2003;57(1):109-118.
33. Mihara K, Aoki T, Moriguchi A, Maeda M, Furuichi Y, Matsuoka N, Mutoh S. Prohemorrhagic and bleeding time activities of recombinant tissue plasminogen activator, heparin, aspirin, and a glycoprotein IIb/IIIa antagonist. J Neurotrauma. 2005;22(11):1362-1373.
34. Wang L, Fan W, Cai P, et al. Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice. Ann Neurol. 2013;73(2): 189-198.
35. Gresele P, Momi S, Berrettini M, Nenci GG, Schwarz HP, Semeraro N, Colucci M. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. J Clin Invest. 1998;101(3): 667-676.
36. Choudhri TF, Hoh BL, Solomon RA, Connolly ES, Pinsky DJ. Use of a spectrophotometric haemoglobin assay to objectively quantify intracerebral hemorrhage in mice. Stroke. 1997; 28(11):2296-2302.
37. De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C. von Willebrand factor: an emerging target in stroke therapy. Stroke. 2012;43(2):599-606.
38. De Meyer SF, Schwarz T, Deckmyn H, et al. Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/ IIIa, contributes to ischemic stroke in mice - brief report. Arterioscler Thromb Vasc Biol. 2010; 30(10):1949-1951.
39. Kulkarni S, Dopheide SM, Yap CL, et al. A revised model of platelet aggregation. J Clin Invest. 2000; 105(6):783-791.
40. Jackson SP, Nesbitt WS, Westein E. Dynamics of platelet thrombus formation. J Thromb Haemost. 2009;7(Suppl 1):17-20.
41. Boulaftali Y, Lamrani L, Rouzaud MC, Loyau S, Jandrot-Perrus M, Bouton MC, Ho-Tin-Noé B. The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy. Thromb Haemost. 2012;107(5): 962-971.
42. Fujioka M, Hayakawa K, Mishima K, et al. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood. 2010;115(8):1650-1653.
43. Zhao BQ, Chauhan AK, Canault M, et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood. 2009;114(15):3329-3334.
44. del Zoppo GJ, Mabuchi T. Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab. 2003;23(8):879-894.
45. Yamamoto J, Ishii I, Okita N, et al. The differential involvement of von Willebrand factor, fibrinogen and fibronectin in acute experimental thrombosis in rat cerebral and mesenteric microvessels. Jpn J Physiol. 1997;47(5):431-441.
46. Firbas C, Siller-Matula JM, Jilma B. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther. 2010; 8(12):1689-1701.
47. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll S. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007; 115(17):2323-2330.
48. Lind SE. The bleeding time does not predict surgical bleeding. Blood. 1991;77(12): 2547-2552.
49. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990; 16(1):1-20.